Indications for Lithium 900 mg and Bupropion 150 mg
Lithium 900 mg daily is indicated for bipolar disorder (acute treatment and maintenance), with additional proven benefits for unipolar depression prevention and suicide prevention, while bupropion 150 mg daily is FDA-approved for major depressive disorder (MDD) and seasonal affective disorder (SAD) prevention. 1, 2, 3
Lithium 900 mg Daily
Primary Indications
Bipolar Disorder is the cornerstone indication for lithium therapy. The medication demonstrates disease-modifying effects beyond mere symptom control 2. For maintenance therapy in bipolar disorder, lithium should be continued for 12-24 months after acute stabilization, with some patients requiring lifelong treatment when benefits outweigh risks 4.
- Therapeutic range: Target 0.6-0.8 mmol/L for most adults 5, 6
- Lower dosing considerations: 0.4-0.6 mmol/L may be appropriate for elderly patients (60-79 years: 0.4-0.8 mmol/L; ≥80 years: 0.4-0.7 mmol/L) 7, 6
- Avoid high doses >1.0 mmol/L due to increased side effects and toxicity risk 2
Additional Evidence-Based Indications
Unipolar Depression Prevention: Lithium has proven efficacy in preventing recurrent episodes of unipolar depression, an underappreciated benefit in current practice 2, 3.
Suicide Prevention: Lithium demonstrates significant anti-suicidal properties across mood disorders, representing a critical indication particularly in high-risk patients 2, 8.
Emerging Applications:
- Neurobiological benefits for cognition and possible dementia prevention 2
- Mood temperaments (cyclothymia, hyperthymia) may benefit from low-dose lithium 2
Critical Monitoring Requirements
Before initiating lithium at 900 mg daily, obtain:
- Complete blood count
- Thyroid function tests (TSH, free T4)
- Renal function (BUN, creatinine, GFR, urinalysis)
- Serum calcium
- Pregnancy test in females of childbearing age 4
Ongoing monitoring every 3-6 months: lithium levels, renal function, thyroid function, urinalysis 4
Contraindications and Cautions
- GFR <30 mL/min/1.73m²: Requires nephrology consultation; critically re-evaluate continuation 6
- GFR <45 mL/min/1.73m²: Do not initiate lithium in elderly patients 6
- Monitor for drug interactions, particularly NSAIDs, diuretics, and ACE inhibitors 8
Bupropion 150 mg Daily
FDA-Approved Indications
Major Depressive Disorder (MDD): Bupropion 150 mg once daily is the FDA-approved starting dose, with potential titration to 300 mg daily after 4 days 1. The medication demonstrated efficacy in controlled trials measuring Hamilton Depression Rating Scale (HAMD) scores and Clinical Global Impressions-Severity Scale (CGI-S) 1.
Seasonal Affective Disorder (SAD) Prevention: Start 150 mg daily for 7 days, then increase to 300 mg daily if tolerated 1. Initiate in autumn before symptom onset, continue through winter, and taper in early spring 1.
Clinical Advantages
- Lower sexual dysfunction compared to SSRIs 9
- Minimal anticholinergic effects 9, 10
- Relatively safe cardiac profile: 10-100 times less likely to cause cardiac conduction problems than tricyclics 10
- Rare orthostatic hypotension 10
Mechanism and Efficacy
Bupropion inhibits presynaptic dopamine and norepinephrine reuptake, with minimal serotonergic effects 9. This profile makes it less likely to provoke mania than serotonergic antidepressants, a relevant consideration when combining with lithium 9.
The medication shows comparable efficacy to other antidepressants and is useful for augmenting partial SSRI responses 9.
Critical Safety Considerations
Seizure risk is the predominant concern:
- Keep total daily dose ≤450 mg in divided doses to maintain seizure rates comparable to other antidepressants 10
- Contraindicated in patients with seizure predisposition 10
- Most common side effects: nervousness, insomnia, dry mouth 9, 10
Dosing Specifics for 150 mg
- Swallow whole; do not crush, divide, or chew 1
- Administer in the morning with or without food 1
- For MDD: May increase to 300 mg after 4 days 1
- For SAD: May increase to 300 mg after 7 days 1
Important Drug Interactions
- Do not combine with MAOIs: Allow 14 days between discontinuing MAOI and starting bupropion, or vice versa 1
- Avoid linezolid or IV methylene blue due to hypertensive reaction risk 1
- Inhibits CYP2D6, raising concern for clinically relevant drug interactions 9
Hepatic/Renal Impairment Adjustments
- Moderate-severe hepatic impairment (Child-Pugh 7-15): Maximum 150 mg every other day 1
- Mild hepatic impairment (Child-Pugh 5-6): Consider dose/frequency reduction 1
- Renal impairment (GFR <90 mL/min): Consider dose/frequency reduction 1
Combined Use Considerations
When prescribing lithium 900 mg and bupropion 150 mg together:
Complementary mechanisms: Lithium's mood-stabilizing effects combined with bupropion's antidepressant action can address bipolar depression without excessive mania risk 9
Monitor for serotonin syndrome risk: Though bupropion has minimal serotonergic effects, remain vigilant when combining psychotropics 1
Suicidality monitoring: Both medications carry black box warnings for increased suicidal thoughts/behaviors in young adults; close monitoring is essential, especially during initiation and dose changes 1
Avoid abrupt discontinuation: Taper bupropion from 300 mg to 150 mg before stopping; gradually discontinue lithium while monitoring for relapse 1, 8